Regeneron Pharmaceuticals (REGN) Return on Sales (2009 - 2026)

Regeneron Pharmaceuticals has reported Return on Sales for 18 years, with the latest figure at 0.0% in Q1 2026.

• For the quarter ending Q1 2026, Return on Sales changed 0.0% year-over-year to 0.0%; the trailing twelve-month figure through Mar 2026 stood at 0.0% (changed 0.0% YoY), and the FY2025 full-year result was 0.0%, changed 0.0% from the prior year.
• Return on Sales for Q1 2026 stood at 0.0%, down from 0.0% in the prior quarter.
• The five-year high for Return on Sales was 0.19% in Q1 2022, with the low at 0.0% in Q1 2026.
• Average Return on Sales over 5 years is 0.02%, with a median of 0.0% recorded in 2023.
• Year-over-year, Return on Sales grew 19 bps in 2022 and dropped 19 bps in 2023.
• Tracing REGN's Return on Sales over 5 years: stood at 0.12% in 2022, then sank by 97 bps to 0.0% in 2023, then retreated by 28 bps to 0.0% in 2024, then retreated by 10 bps to 0.0% in 2025, then dropped by 7 bps to 0.0% in 2026.
• The last three Return on Sales figures came in at 0.0% (Q1 2026), 0.0% (Q4 2025), and 0.0% (Q3 2025), per Business Quant data.

Peer Comparison